Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Aranesp Side Effects Lawsuits | Side Effects: Blood Clots, Death, Arrest, Hypertension, Vascular, thrombosis

Aranesp Side Effects May Link To Hypertension Lawsuits

Aranesp | Lawsuits, Lawyers | Side Effects: Blood Clots, Death, Arrest, Hypertension, Vascular, thrombosis

Aranesp Side Effects

Aranesp Treat Anemia

Aranesp (generic: darbepoetin alfa) is approved to treat anemia caused by chemotherapy. Anemia is a common side effect of chemotherapy, which can damage the production of red blood cells. In anemia, the blood is lacking in healthy red blood cells, which transport oxygen to organs. The FDA approved Aranesp on September 17, 2001.

On January 14, 2005 Amgen and the FDA sent letters to doctors advising them of a revision to the warning label for Aranesp. Two new studies with other drugs in the same class of Aranesp, known as erythropoietic drugs, have shown that using the drugs at higher-than-recommended doses increases the risk of adverse effects including blood clots and death.

Other life threatening side effects of Aranesp include cardiac arrest, hypertension, vascular thrombosis and convulsions.

Although the studies were conducted with other drugs (Eprex and NeoRecormon), Amgen has incorporated this information into the prescribing information for Aranesp to alert doctors to these potential risks.

Need Legal Help Regarding Aranesp Side Effects?

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).



AranespRSS Feed

Sales of Potentially Dangerous Anemia Drugs Raise Questions

Jul 19, 2012 | Parker Waichman LLP
Three popular anemia drugs may have generated billions of dollars in revenue for two companies but they’ve proven to be dangerous and a drain on the federal health care system and patients’ wallets. An investigation launched by The Washington Post reveals that Amgen and Johnson & Johnson enacted an aggressive lobbying effort to federal health officials and on the back of research that clearly missed the dangers of the drugs Epogen, Procrit, and Aranesp. Amgen was able to gain...

FDA Says Another Safety Review of Anemia Drugs in the Works

Jan 7, 2010 | Parker Waichman LLP
Anemia drugs Procrit, Epogen and Aranesp are slated to undergo another safety review, following the publication of a clinical trail that linked one of them to an increased risk of stroke. According to The New York Times, that study, called “Treat” was published in October in the New England Journal of Medicine. The goal of Treat was to see if using Aranesp to increase the red blood cell levels of people with diabetes and kidney disease would prevent death and cardiovascular...

Procrit, Similar Drugs Linked to Increased Death Risk By Two More Studies

May 5, 2009 | Parker Waichman LLP
Two more studies have found that anemia drugs like Epogen, Procrit and Aranesp raise the risk of death among cancer patients.  Despite known safety risks, drugs like Procrit continue to be used because it is believed that they help reduce the number of blood transfusions some cancer patients need, while improving quality of life. According to a report on,  these two studies may raise  questions about that theory.Epogen, Procrit and Aranesp are known as...

Amgen Ends Controversial Aranesp Marketing Practices

Aug 29, 2008 | Parker Waichman LLP
The maker of Aranesp is halting marketing practices that critics said encouraged over-use of the anemia drug.  Criticism of the policies, in which Amgen  paid rebates to doctors for the purchase of Aranesp, had grown along with questions about the drug's safety. Aranesp is an erythropoiesis-stimulating agent (ESA).  Two other ESA's, Epogen and Procrit, are also currently available.   All are made by Amgen, but Procrit is sold by Johnson & Johnson subsidiary Ortho...

More than 44,000 Vials of Procrit Recalled

Aug 6, 2008 | Parker Waichman LLP
Procrit is being recalled by Johnson & Johnson subsidiary Ortho Biotech.  According to the company's recall notice, the action is necessary because cracks in the necks of a small number of Procrit vials were discovered upon post-manufacturing inspection.The Procrit recall involves approximately 44,292 vials of lot P114942A distributed between April 15, 2008 and July 17, 2008.  The recalled Procrit vials were available in  the following packaging configurations: Individual...

More Aranesp News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo